- Language: English
- 600 Pages
- Published: March 2014
- Region: Global
Global Dermatophytic Onychomycosis Therapeutics Market 2012-2016
- Published: September 2013
- Region: Global
- 67 pages
The analysts forecast the Global Dermatophytic Onychomycosis Therapeutics market to grow at a CAGR of 7.28 percent over the period 2012-2016. One of the key factors contributing to this market growth is the strong and promising pipeline. The Global Dermatophytic Onychomycosis Therapeutics market has also been witnessing an increased focus on combination therapies for the treatment of dermatophytic onychomycosis. However, the adverse side effects associated with drugs could pose a challenge to the growth of this market.
The report, Global Dermatophytic Onychomycosis Therapeutics Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Dermatophytic Onychomycosis Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Anacor Pharmaceuticals Inc., Celtic Pharmaceutical Holdings L.P., Genelabs Technologies Inc., Hisamitsu Pharmaceutical Co. Inc., Janssen Biotech Inc., Mayne Pharma Ltd., Merck & Co. Inc., NanoBio Corp., Novartis International AG, Palau Pharma S.A., Pfizer Inc., Promius Pharma LLC , Stiefel laboratories Inc., Topica Pharmaceuticals Inc., Valeant Pharmaceuticals International
Key questions answered in this report:
- What will the market size be in 2016 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of these key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report. SHOW LESS READ MORE >
01. Executive Summary
02. Scope of the Report
02.1 Market Overview
02.2 Product Offerings
03. Market Research Methodology
03.1 Market Research Process
03.2 Research Design
03.3 Research Methodology
04. List of Abbreviations
06. Types of Dermatophytic Onychomycosis
06.1.1 Distal Subungual Onychomycosis
06.1.2 Proximal Subungual Onychomycosis
06.1.3 White Superficial Onychomycosis
06.1.4 Candidal Onychomycosis
07. Currently Approved Drugs
07.1 Oral Agents
07.2 Topical Agents
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Dermatophytic Onychomycosis Market in the US
08.3.1 Market Segmentation
08.3.2 Itraconazole Sales in the US
08.3.3 Flucanozole Sales in the US
08.3.4 Griseofulvin Sales in the US
08.3.5 Ketoconazole Sales in the US
08.4 Five Forces Analysis
09. Geographical Segmentation
09.1 Global Dermatophytic Onychomycosis Therapeutics Market by Geographical Segmentation 2012-2016
10. Rate of Incidence and Prevalence
11. Pipeline Analysis
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Other Prominent Vendors
20. Key Vendor Analysis
20.1 Anacor Pharmaceuticals Inc.
20.1.1 Business Overview
20.1.2 Key Information
20.1.3 SWOT Analysis
20.2 Janssen Biotech Inc.
20.2.1 Business Overview
20.2.2 Key Information
20.2.3 SWOT Analysis
20.3 Novartis International AG
20.3.1 Business Overview
20.3.2 Business Segmentation
20.3.3 Key Information
20.3.4 SWOT Analysis
20.4 Pfizer Inc.
20.4.1 Business Overview
20.4.2 Business Segmentation
20.4.3 Key Information
20.4.4 SWOT Analysis
21. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Nail Unit Dorsal and Lateral View
Exhibit 3: Types of Dermatophytic Onychomycosis
Exhibit 4: Global Dermatophytic Onychomycosis Therapeutics Market Overview
Exhibit 5: Global Dermatophytic Onychomycosis Therapeutics Market 2012-2016 (US$ billion)
Exhibit 6: Dermatophytic Onychomycosis Therapeutics Market in the US 2012-2016 (US$ million)
Exhibit 7: Dermatophytic Onychomycosis Market in the US Segmentation
Exhibit 8: Itraconazole Sales in the US 2012-2016 (US$ million)
Exhibit 9: Fluconazole Sales in the US 2012-2016 (US$ million)
Exhibit 10: Griseofulvin Sales in the US 2012-2016 (US$ million)
Exhibit 11: Ketoconazole Sales in the US 2012-2016 (US$ million)
Exhibit 12: Global Dermatophytic Onychomycosis Therapeutics Market by Geographical Segmentation 2012
Exhibit 13: Business Segmentation of Novartis International AG
Exhibit 14: Business Segmentation of Pfizer Inc.
Commenting on the report, an analyst from the team said: “A current trend witnessed in the Global Dermatophytic Onychomycosis Therapeutics market is the use of combination therapies for treating dermatophytic onychomycosis. It has been found that a combination of topical and systemic treatment increases the cure rate when compared to the single therapy. A combination of amorolfine nail lacquer and oral terbinafine is the most commonly used combination therapy. It has improved clinical efficiency and is more cost-effective than terbinafine alone. At times the combination of surgery and systemic and topical therapies are also used in treatment. Moreover, sometimes non-pharmacological approaches such as laser treatment; mechanical treatment is also used in combination with topical and systemic therapy. This trend will have a positive impact on the growth of the market.”
According to the report, the growth of the Global Dermatophytic Onychomycosis Therapeutics market is driven by several factors, the most important of which is the strong and promising pipeline of drugs that have disease-modifying properties and a better safety and efficacy profile.
Further, the report states that one of the key challenges in the market is the risk of side effects associated with dermatophytic onychomycosis drugs. These side effects are hampering the acceptance of advanced drugs for the treatment of moderate to severe dermatophytic onychomycosis.
The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are Celtic Pharmaceutical Holdings L.P., Genelabs Technologies Inc., Hisamitsu Pharmaceutical Co. Inc., Mayne Pharma Ltd., Merck & Co. Inc., NanoBio Corp., Palau Pharma S.A., Promius Pharma LLC, Stiefel Laboratories Inc., Topica Pharmaceuticals Inc., and Valeant Pharmaceuticals International.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
- Anacor Pharmaceuticals Inc.
- Celtic Pharmaceutical Holdings L.P.
- Genelabs Technologies Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- Janssen Biotech Inc.
- Mayne Pharma Ltd.
- Merck & Co. Inc.
- NanoBio Corp.
- Novartis International AG
- Palau Pharma S.A.
- Pfizer Inc.
- Promius Pharma LLC
- Stiefel laboratories Inc.
- Topica Pharmaceuticals Inc.
- Valeant Pharmaceuticals International